Open AccessCompelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic
Author(s) -
Díez Javier,
BayesGenis Antoni
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007665
Subject(s) - medicine , myocardial infarction , cardiology
It is estimated that in the United States, each year, u003e780 000 people will experience an acute coronary syndrome. Approximately 70% of these people will have a non–ST‐elevated myocardial infarction (NSTEMI), and the rest will have an ST‐elevated myocardial infarction (STEMI).[1][1] Patients